Forecasts data is unavailable for this security.
Consensus recommendation
- 14-Dec-23
- 19-Sep-24
- 17-Oct-24
- 14-Nov-24
- 21-Nov-24
Select bar for recommendation details.
Recommendations | 21-Nov-24 | |
---|---|---|
Buy | 0 | |
Outperform | 1 | |
Hold | 9 | |
Sell | 0 | |
Strong Sell | 0 |
Share price forecast in USD
The 8 analysts offering 12 month price targets for Revance Therapeutics Inc have a median target of 6.66, with a high estimate of 25.00 and a low estimate of 6.00. The median estimate represents a 73.44% increase from the last price of 3.84.
High | 551.0% | 25.00 |
Med | 73.4% | 6.66 |
Low | 56.3% | 6.00 |
Earnings history & estimates in USD
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate | +25.89% |
Average growth rate | -3.47% |
More ▼
Revenue history & estimates in USD
Average growth rate | +3.71% |
Average growth rate | +1,041.31% |
More ▼